PMGC Holdings Inc. - Common Stock (ELAB)

5.9900
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 1st, 5:12 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
A new wave of market-moving developments across biotech, defense technology, and emerging growth companies is putting Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Virtuix Holdings, Inc. (NASDAQ: VTIX) , PMGC Holdings Inc. (NASDAQ: ELAB) , and Artelo Biosciences, Inc. (NASDAQ: ARTL) firmly on investor watchlists. Biotech M&A activity, defense-driven VR adoption, strategic capital deployment, and fresh funding catalysts are all contributing to rising investor interest across multiple high-growth sectors.
Via AB Newswire · March 31, 2026
AGA Precision Systems Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products
NEWPORT BEACH, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- AGA Precision Systems LLC (“AGA”), a precision aerospace manufacturing company and wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today announced the execution of a Long-Term agreement (“LTA”) with Turbo-Jet Products Co., Inc. (“Turbo-Jet Products”), a California-based aerospace and defense supplier.
By PMGC Holdings Inc. · Via GlobeNewswire · March 31, 2026
PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
NEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE 2025”), with the U.S. Securities and Exchange Commission (“SEC”).
By PMGC Holdings Inc. · Via GlobeNewswire · March 30, 2026
NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments
NEWPORT BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.’s (NASDAQ: ELAB) (“PMGC,” “we,” or “our”) wholly owned subsidiary, NorthStrive Biosciences Inc. (“Northstrive Biosciences”), announced today a third amendment (“Amendment”) to its existing License Agreement with MOA Life Plus Co., Ltd., [KOSDAQ: 142760] a Korean biotechnology company (“MOA,” and such existing agreement, as amended, “License Agreement”) Northstrive Biosciences holds for EL-32 and EL-22.
By PMGC Holdings Inc. · Via GlobeNewswire · March 27, 2026
SVM Machining, Inc. Secures ITAR Registration, Enabling Entry into U.S. Defense Manufacturing Contracts
NEWPORT BEACH, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: PMGC) (“PMGC” or the “Company”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, SVM Machining, Inc. dba Silicon Valley Manufacturing (“SVM”), has completed International Traffic in Arms Regulations (“ITAR”) registration and is in compliance with ITAR. The ITAR is administered by the U.S. State Department’s Directorate of Defense Trade Controls, which controls the export and import of defense articles and services.
By PMGC Holdings Inc. · Via GlobeNewswire · March 24, 2026
NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences”). The study is designed to evaluate EL-32’s potential to preserve lean muscle mass while promoting fat loss, both as a standalone therapy and in combination with GLP-1 weight loss treatments.
By PMGC Holdings Inc. · Via GlobeNewswire · March 10, 2026
PMGC Holdings Inc. Announces Anticipated Reverse Stock Split
NEWPORT BEACH, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-6 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on March 10, 2026.
By PMGC Holdings Inc. · Via GlobeNewswire · March 4, 2026
NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal.
By PMGC Holdings Inc. · Via GlobeNewswire · February 19, 2026
GB Capital Ltd. Co-Advises on the Acquisition of SVM Machining, Inc.
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- GB Capital Ltd. (“GB Capital”), a strategic finance, advisory and management firm, today announced that it served as co-advisor to PMGC Holdings  Inc. (NASDAQ: ELAB) (“PMGC”) in connection with PMGC’s acquisition of SVM Machining, Inc. (“SVM”), a Northern California–based ISO 9001:2015 certified CNC precision machining company.
By GB Capital Ltd. · Via GlobeNewswire · February 12, 2026
NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health
NEWPORT BEACH, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced that it has executed a definitive, exclusive license agreement (“License Agreement”) with Modulant Biosciences LLC (“Modulant”), following the previously announced binding term sheet dated May 12, 2025.
By PMGC Holdings Inc. · Via GlobeNewswire · February 11, 2026
NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
NEWPORT BEACH, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today announced a progress update to the anticipated completion timeline for Phase III of its AI Development Program with strategic partner Yuva Biosciences, Inc. (“Yuva Biosciences”).
By PMGC Holdings Inc. · Via GlobeNewswire · February 4, 2026
PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.
NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. (“SVM”).
By PMGC Holdings Inc. · Via GlobeNewswire · February 3, 2026
PMGC Holdings Inc. Announces Strategic Share Acquisition in Micro Modular Reactor (MMR) Focused Nuclear Energy Company, Nuclea Energy Inc.
NEWPORT BEACH, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”), a diversified public holding company with multiple operating subsidiaries announces its investment arm PMGC Capital LLC. (“PMGC Capital”), has invested and acquired non-controlling shares in Nuclea Energy Inc. (“Nuclea Energy”), a company focused on the development and advancement of Micro Modular Reactor (MMR) and advanced nuclear energy solutions. The investment closed on November 6, 2025.
By PMGC Holdings Inc. · Via GlobeNewswire · January 6, 2026
PMGC Holdings Inc. Announces Reverse Stock Split Effective January 6, 2026
NEWPORT BEACH, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that, as previously disclosed on January 2, 2026, it will effect a 1-for-4 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 9:00 am, Eastern time, on January 6, 2026.
By PMGC Holdings Inc. · Via GlobeNewswire · January 5, 2026
PMGC Holdings Inc. Announces Anticipated Reverse Stock Split
NEWPORT BEACH, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-4 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 9:00 am, Eastern time, on January 6, 2026.
By PMGC Holdings Inc. · Via GlobeNewswire · January 2, 2026
AGA Precision Systems LLC Achieves Globally Recognized AS9100 Certification for Aerospace, Defense, and Space Manufacturing, Exploring Future Humanoid Robotics Integration
NEWPORT BEACH, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC,” the “Company,” “we,” or “our”) today announced that its wholly owned subsidiary, AGA Precision Systems LLC (“AGA”), successfully achieved AS9100 certification, the globally recognized quality management standard specific to the aerospace, defense and space industries.
By PMGC Holdings Inc. · Via GlobeNewswire · December 22, 2025
NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries
NEWPORT BEACH, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC” or the “Company”), today announced the initiation of Phase III of its AI Development Program (“AI Development Program”) with Yuva Biosciences, Inc. (“YuvaBio”) under the Development and License Agreement ("Agreement") between the parties. Phase III will advance AI-driven compound identification in Phase II of the AI Development Program to experimental validation, marking a significant step towards advancing NorthStrive Biosciences’ pipeline of therapies addressing obesity and related metabolic conditions.
By PMGC Holdings Inc. · Via GlobeNewswire · December 17, 2025
PMGC Holdings Inc. [Nasdaq: ELAB] Congratulates General Enterprise Ventures, Inc. [NYSE: CITR] on Its Uplisting to the NYSE American, Highlights Equity Stake
NEWPORT BEACH, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”), and its operating investment division, PMGC Capital LLC (“PMGC Capital”), congratulates General Enterprise Ventures, Inc. (NYSE American: CITR) on its uplisting to the NYSE American.
By PMGC Holdings Inc. · Via GlobeNewswire · December 4, 2025
PMGC Holdings Inc. Announces AGA Precision Systems LLC’s ITAR (International Traffic in Arms Regulations) Registration Approval
NEWPORT BEACH, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: PMGC) (“PMGC” or the “Company”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, AGA Precision Systems LLC (“AGA Precision Systems” or “AGA”), has completed International Traffic in Arms Regulations (ITAR) registration and is in compliance with ITAR. The ITAR is administered by the U.S. State Department’s Directorate of Defense Trade Controls, which controls the export and import of defense articles and services.
By PMGC Holdings Inc. · Via GlobeNewswire · October 30, 2025
PMGC Holdings Inc.’s Subsidiary, AGA Precision Systems LLC, Completes Acquisition of Indarg Engineering, Inc. Expanding Aerospace and Defense Manufacturing Platform
NEWPORT BEACH, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: PMGC) (“PMGC” or the “Company”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its wholly owned subsidiary, AGA Precision Systems LLC (“AGA”), has acquired all operating assets of Indarg Engineering, Inc., a precision computer numerical control (“CNC”) machining company based in Hawthorne, California.
By PMGC Holdings Inc. · Via GlobeNewswire · October 28, 2025
PMGC Holdings Inc. Announces Over $711,000.00 in Sales Backlog at AGA Precision Systems LLC and Provides Corporate Update
NEWPORT BEACH, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company” or “we”), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its operating subsidiary AGA Precision Systems LLC (“AGA”) has reported a sales backlog of approximately over $711,000 in current orders logged into its Material Requirements Planning system, Sage100. AGA has also confirmed that it is actively bidding on additional Request for Quotations totaling over $700,000 from new customers. PMGC believes AGA’s current backlog and pending orders reflect robust demand, underscoring AGA’s growth momentum and the strong relationships it continues to build with both existing and new customers. PMGC also believes the backlog and pending orders strengthen AGA’s position to expand its precision machining capabilities within the aerospace and defense sectors. The backlog and quotation figures referenced herein are internally prepared, unaudited, management estimates and remain subject to change.
By PMGC Holdings Inc. · Via GlobeNewswire · October 20, 2025
Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases
NEWPORT BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of Phase II of the AI Development Program (“Phase II”) with strategic partner Yuva Biosciences, Inc. (“YuvaBio”). As part of the Phase II objective, YuvaBio delivered to Northstrive a shortlist of small molecule candidates YuvaBio believes has the potential to promote mitochondrial health to combat obesity and cardiac diseases.
By PMGC Holdings Inc. · Via GlobeNewswire · September 4, 2025
PMGC Holdings Inc. Announces Anticipated Reverse Stock Split
NEWPORT BEACH, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-3.5 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”). The marketplace effective date of the Split will be September 2, 2025 at 9:30 am EST.
By PMGC Holdings Inc. · Via GlobeNewswire · August 28, 2025
PMGC Holdings Inc. Announces $1.67 Million in Gross Proceeds from Warrant Inducement with Institutional Investors Priced At-The Market Under Nasdaq Rules
NEWPORT BEACH, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding warrants that the Company issued on January 27, 2025. Pursuant to the warrant inducement agreement, the investors have agreed to exercise the outstanding warrants to purchase an aggregate of 827,900 shares of the Company's common stock at an amended exercise price of $2.015. The gross proceeds from the exercise of the warrants are expected to be approximately $1.67 million, prior to deducting placement agent fees and estimated offering expenses.
By PMGC Holdings Inc. · Via GlobeNewswire · August 22, 2025
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q
NEWPORT BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months and six months ended June 30, 2025, with the U.S. Securities and Exchange Commission (“SEC”).
By PMGC Holdings Inc. · Via GlobeNewswire · August 13, 2025